Toxicological Research

  • 제39권1호
  • /
  • Pages.61-69
  • /
  • 2023
  • /
  • 1976-8257(pISSN)
  • /
  • 2234-2753(eISSN)
한국독성학회 (Korean Society of Toxicology & Korea Environmental Mutagen Society)
권호 표지
DOI QR코드

DOI QR Code

CKD-516 potentiates the anti-cancer activity of docetaxel against epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer

  • Soo Jin, Kim (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University) ;
  • Kyunghyeon, Lee (CKD Research Institution, Chong Kun Dang Pharmaceutical Corporation) ;
  • Jaewoo, Park (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University) ;
  • Miso, Park (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University) ;
  • U. Ji, Kim (CKD Research Institution, Chong Kun Dang Pharmaceutical Corporation) ;
  • Se-mi, Kim (CKD Research Institution, Chong Kun Dang Pharmaceutical Corporation) ;
  • Keun Ho, Ryu (CKD Research Institution, Chong Kun Dang Pharmaceutical Corporation) ;
  • Keon Wook, Kang (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University)
  • 투고 : 2022.05.05
  • 심사 : 2022.07.12
  • 발행 : 2023.01.15
⟨ 이전 논문 다음 논문 ⟩

초록

Lung cancer is the leading cause of cancer death. Although docetaxel has been used as a second- or third-line treatment for non-small cell lung cancer (NSCLC), the objective response rate is less than 10%. Hence, there is a need to improve the clinical efficacy of docetaxel monotherapy; combination therapy should be considered. Here, we show that CKD-516, a vascular disruption agent, can be combined with docetaxel to treat epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)-resistant NSCLC. CKD-516 was orally bioavailable; neither CKD-516 nor docetaxel affected the mean plasma concentration-time profile or pharmacokinetic parameters of the other drug. CKD-516 and docetaxel synergistically inhibited the growth of H1975 (with an L858R/T790M double mutation of EGFR) and A549 (with a KRAS mutation) lung cancer cell lines. In addition, docetaxel plus CKD-516 delayed tumor growth in-and extended the lifespan of-tumor-bearing mice. Thus, combination CKD-516 and docetaxel therapy could be used to treat EGFR-TKI-resistant NSCLC.

키워드

과제정보

This research was funded by the National Research Foundation of Korea (NRF) grant 2021R1A2C2093196.

참고문헌

  1. Herbst RS, Morgensztern D, Boshoff C (2018) The biology and management of non-small cell lung cancer. Nature 553:446-454. https://doi.org/10.1038/nature25183
  2. Alexander M, Kim SY, Cheng H (2020) Update 2020: Management of non-small cell lung cancer. Lung 198:897-907. https://doi.org/10.1007/s00408-020-00407-5
  3. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103. https://doi.org/10.1200/JCO.2000.18.10.2095
  4. Weiss JM, Stinchcombe TE (2013) Second-Line Therapy for Advanced NSCLC. Oncologist 18:947-953. https://doi.org/10.1634/theoncologist.2013-0096
  5. Hinnen P, Eskens FA (2007) Vascular disrupting agents in clinical development. Br J Cancer 96:1159-1165. https://doi.org/10.1038/sj.bjc.6603694
  6. Hollebecque A, Massard C, Soria JC (2012) Vascular disrupting agents: a delicate balance between efficacy and side effects. Curr Opin Oncol 24:305-315. https://doi.org/10.1097/CCO.0b013e32835249de
  7. Mita MM, Sargsyan L, Mita AC, Spear M (2013) Vascular-disrupting agents in oncology. Expert Opin Investig Drugs 22:317-328. https://doi.org/10.1517/13543784.2013.759557
  8. Kim SJ, Jegal KH, Im JH, Park G, Kim S, Jeong HG, Cho IJ, Kang KW (2020) Involvement of ER stress and reactive oxygen species generation in anti-cancer effect of CKD-516 for lung cancer. Cancer Chemother Pharmacol. https://doi.org/10.1007/s00280-020-04043-x
  9. Smolarczyk R, Czapla J, Jarosz-Biej M, Czerwinski K, Cichon T (2021) Vascular disrupting agents in cancer therapy. Eur J Pharmacol 891:173692. https://doi.org/10.1016/j.ejphar.2020.173692
  10. Kim KW, Lee JM, Jeon YS, Lee IJ, Choi Y, Park J, Kiefer B, Kim C, Han JK, Choi BI (2013) Vascular disrupting effect of CKD-516: preclinical study using DCE-MRI. Invest New Drugs 31:1097-1106. https://doi.org/10.1007/s10637-012-9915-6
  11. Oh DY, Kim TM, Han SW, Shin DY, Lee YG, Lee KW, Kim JH, Kim TY, Jang IJ, Lee JS, Bang YJ (2016) Phase I study of CKD-516, a novel vascular disrupting agent, in patients with advanced solid tumors. Cancer Res Treat 48:28-36. https://doi.org/10.4143/crt.2014.258
  12. Marcath LA, Coe TD, Hoylman EK, Redman BG, Hertz DL (2018) Prevalence of drug-drug interactions in oncology patients enrolled on national clinical trials network oncology clinical trials. BMC Cancer 18:1155. https://doi.org/10.1186/s12885-018-5076-0
  13. Royer I, Monsarrat B, Sonnier M, Wright M, Cresteil T (1996) Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res 56:58-65. PMID: 8548776. https://www.ncbi.nlm.nih.gov/pubmed/8548776 CAS Google Scholar
  14. Engels FK, Ten Tije AJ, Baker SD, Lee CK, Loos WJ, Vulto AG, Verweij J, Sparreboom A (2004) Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther 75:448-454. https://doi.org/10.1016/j.clpt.2004.01.001
  15. Mhaidat NM, Zhang XD, Jiang CC, Hersey P (2007) Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway. Clin Cancer Res 13:1308-1314. https://doi.org/10.1158/1078-0432.CCR-06-2216
  16. Moon CH, Lee SJ, Lee HY, le Dung TK, Cho WJ, Cha H, Park JW, Min YJ (2014) CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model. Invest New Drugs 32:400-411. https://doi.org/10.1007/s10637-013-0043-8
  17. Onodera K, Sakurada A, Notsuda H, Watanabe T, Matsuda Y, Noda M, Endo C, Okada Y (2018) Growth inhibition of KRAS and EGFRmutant lung adenocarcinoma by cosuppression of STAT3 and the SRC/ARHGAP35 axis. Oncol Rep 40:1761-1768. https://doi.org/10.3892/or.2018.6536
  18. Wang ES, Pili R, Seshadri M (2012) Modulation of chemotherapeutic efficacy by vascular disrupting agents: optimizing the sequence and schedule. J Clin Oncol 30:760-761; author reply 761-763. https://doi.org/10.1200/JCO.2011.39.3934
  19. Clemenson C, Chargari C, Deutsch E (2013) Combination of vascular disrupting agents and ionizing radiation. Crit Rev Oncol Hematol 86:143-160. https://doi.org/10.1016/j.critrevonc.2012.10.002
  20. Schwartz GK, Shah MA (2005) Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 23:9408-9421. https://doi.org/10.1200/JCO.2005.01.5594
  21. Nehme A, Varadarajan P, Sellakumar G, Gerhold M, Niedner H, Zhang Q, Lin X, Christen RD (2001) Modulation of docetaxel-induced apoptosis and cell cycle arrest by all- trans retinoic acid in prostate cancer cells. Br J Cancer 84:1571-1576. https://doi.org/10.1054/bjoc.2001.1818
  22. Singh AV, Bandi M, Raje N, Richardson P, Palladino MA, Chauhan D, Anderson KC (2011) A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells. Blood 117:5692-5700. https://doi.org/10.1182/blood-2010-12-323857
  23. Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39:1-10. https://doi.org/10.1016/j.immuni.2013.07.012
  24. Kashyap AS, Fernandez-Rodriguez L, Zhao Y, Monaco G, Trefny MP, Yoshida N, Martin K, Sharma A, Olieric N, Shah P, Stanczak M, Kirchhammer N, Park SM, Wieckowski S, Laubli H, Zagani R, Kasenda B, Steinmetz MO, Reinecker HC, Zippelius A (2019) GEF-H1 signaling upon microtubule destabilization is required for dendritic cell activation and specific anti-tumor responses. Cell Rep 28(3367-3380):e3368. https://doi.org/10.1016/j.celrep.2019.08.057
  25. Kim SJ, Kim HK, Ryu KH, Hong CI (2019) Abstract 3216: CKD-516, a novel vascular disrupting agent, enhances anticancer activity of anti-PD-1 antibody in SMAD4-deficient colon cancer model. Can Res 79:3216-3216. https://doi.org/10.1158/1538-7445.AM2019-3216
  26. Spear MA, LoRusso P, Mita A, Mita M (2011) Vascular disrupting agents (VDA) in oncology: advancing towards new therapeutic paradigms in the clinic. Curr Drug Targets 12:2009-2015. https://doi.org/10.2174/138945011798829366